Skorupan Nebojsa, Palestino Dominguez Mayrel, Ricci Samuel L, Alewine Christine
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Medical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cancers (Basel). 2022 Aug 30;14(17):4209. doi: 10.3390/cancers14174209.
Pancreatic cancer has a complex tumor microenvironment which engages in extensive crosstalk between cancer cells, cancer-associated fibroblasts, and immune cells. Many of these interactions contribute to tumor resistance to anti-cancer therapies. Here, new therapeutic strategies designed to modulate the cancer-associated fibroblast and immune compartments of pancreatic ductal adenocarcinomas are described and clinical trials of novel therapeutics are discussed. Continued advances in our understanding of the pancreatic cancer tumor microenvironment are generating stromal and immune-modulating therapeutics that may improve patient responses to anti-tumor treatment.
胰腺癌具有复杂的肿瘤微环境，癌细胞、癌症相关成纤维细胞和免疫细胞之间存在广泛的相互作用。其中许多相互作用导致肿瘤对抗癌治疗产生耐药性。本文描述了旨在调节胰腺导管腺癌的癌症相关成纤维细胞和免疫细胞区室的新治疗策略，并讨论了新型疗法的临床试验。我们对胰腺癌肿瘤微环境认识的不断进步正在催生基质和免疫调节疗法，有望改善患者对抗肿瘤治疗的反应。
